drugset / Trial / NCT00473824
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2 study to evaluate safety, pharmacokinetics and efficacy of Hepatitis C Immune Globulin Intravenous (human) \[Civacir(TM)\] for preventing or reducing the impact of recurrent HCV infection following liver transplantation.
Timeline
- Start
- 2007-05
- Primary completion
- 2009-02
- Completion
- 2009-02
Outcome
Outcome not reported
Stopped: “New sponsor's decision to pursue a redesigned clinical study”